FX006 32 mg
FX006-2019-017
Phase 2 small_molecule completed
Quick answer
FX006 32 mg for Osteoarthritis, Hip is a Phase 2 program (small_molecule) at Pacira BioSciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pacira BioSciences
- Indication
- Osteoarthritis, Hip
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed